Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (70)	7/17/2000 4:24:23 PM
From: RCMac	Read Replies (1) \| Respond to of 724

>> Please list for me...... all biotechs with market caps of minus $45 million. << And, scrolling forward a year or so to a later perspective, how many biotechs with a negative valuation stayed that way for very long, absent gross mismanagement as opposed to (usually temporary) market blindness? I recall that in the last couple of years the silly market has offered us, for example: BTRN at 1.00/share when it had $3.00/share in cash ( sellers paying you to take off their hands the commercial rights to the output of the foremost transplant biology lab in the world [Harvard/MGH] )- BTRN now at 11. NBIX at 3 3/4 last August when it had $3.00 in cash and five phase II trials going, and still owned (as it still does) all of its insomnia medication - NBIX now at 38 1/2. MLNM at about [split-adjusted] $6.50. etc., etc. My guess is that NBSC's absurdly low price shouldn't last long. I'll wait, holding my 50% or so gains so far, expecting a lot more when the market notices. --RCM